The Full Wiki

More info on Bertilimumab

Bertilimumab: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Bertilimumab ?
Monoclonal antibody
Source Human
Target CCL11 (eotaxin-1)
Identifiers
CAS number 375348-49-5
ATC code none
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1.

It was discovered by Cambridge Antibody Technology using their phage display technology[1]. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders[2].

In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3]. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'[4].

iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis[5].

In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]

References

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message